If you are researching Wegovy, the first question is usually simple: how much weight will I actually lose? The honest answer is that no one can promise a number, but the clinical trials that led to Wegovy's FDA approval give a clear, published picture of what the medication did on average. This article walks through those trial results, builds a realistic timeline from them, and explains the factors that move individual outcomes up or down.
One rule shapes everything below: every percentage here is a named, published trial average. None of it is a promise of what you will lose. Individual results vary.
The Headline Number: STEP-1
The pivotal trial for Wegovy was STEP-1, published in the New England Journal of Medicine in 2021. It enrolled 1,961 adults with obesity (or overweight with a weight-related condition) who did not have diabetes.
At week 68, the results were:
For a person starting at 230 pounds, a 14.9% average would represent roughly 34 pounds. That is an average across nearly two thousand people. Some lost far more, some lost much less, and the spread was wide. Individual results vary.
It is also worth noting what STEP-1 included beyond the injection: every participant received lifestyle support, including counseling on reduced-calorie diet and increased physical activity. The trial measured the medication plus structured lifestyle support, not the medication alone.
STEP-3: Adding Intensive Behavioral Therapy
STEP-3 tested whether more intensive lifestyle intervention changed the picture. It paired semaglutide 2.4 mg with intensive behavioral therapy and an initial low-calorie diet.
At week 68, the average body weight reduction on semaglutide in STEP-3 was about 16.0%, compared with roughly 5.7% on placebo (both groups received the intensive behavioral support). The takeaway is that structured diet and behavior support can add to the average outcome, though the medication remained the largest driver of the difference between groups. Individual results vary.
STEP-4: What Happens If You Stop
STEP-4, published in JAMA in 2021, is one of the most important trials for setting expectations, because it studied stopping.
All participants first took semaglutide for 20 weeks (the run-in titration period). At week 20, they were split into two groups: one continued semaglutide, the other switched to placebo. Researchers then followed both groups to week 68.
The results:
The lesson clinicians take from STEP-4 is straightforward: for many people, the weight loss is maintained while the medication and supporting habits continue, and a meaningful portion returns when the medication stops. This is consistent with how the medical field now views obesity, as a chronic condition rather than something cured by a short course. Individual results vary.
STEP-5: The Two-Year Picture
Most GLP-1 trials run about 68 to 72 weeks. STEP-5 extended the timeline to two years (104 weeks) to see whether results held.
At week 104, the average body weight reduction on semaglutide 2.4 mg was about 15.2%, compared with roughly 2.6% on placebo. The practical message is that, on average, the weight loss achieved in the first year was largely sustained into the second year for participants who stayed on treatment with lifestyle support. The curve flattens, which is expected, but it did not simply reverse. Individual results vary.
A Realistic Month-by-Month Timeline
People want a week-by-week or month-by-month map. The honest version of that map is built from how the STEP trials dosed and how their average curves behaved. Wegovy is titrated slowly, so the early months are mostly about reaching the target dose, not maximum weight loss.
Here is a trial-informed framing. Treat every figure as an average pattern, not a personal forecast. Individual results vary.
| Timeframe | Typical dose phase | What the trial averages showed |
|---|---|---|
| Month 1 (weeks 1 to 4) | 0.25 mg starter | Small average change; many people notice reduced appetite before the scale moves much |
| Month 2 (weeks 5 to 8) | 0.5 mg | Gradual loss begins as appetite signaling shifts |
| Month 3 (weeks 9 to 12) | 1.0 mg | Loss becomes more consistent for many participants |
| Month 4 (weeks 13 to 16) | 1.7 mg | Approaching therapeutic range; rate of loss often picks up |
| Months 5 to 9 | 2.4 mg target | The steepest part of the average STEP-1 curve |
| Months 10 to 16 | 2.4 mg maintenance | Loss continues but slows; average approaches the 14.9% week-68 figure |
| Year 2 | 2.4 mg maintenance | STEP-5 average held near 15.2% with continued treatment |
### Wegovy 1 month results
Because month one is the 0.25 mg starter dose, it is a tolerability step, not a full therapeutic dose. In the STEP trials, early weight changes were modest and varied widely. Some participants reported reduced appetite quickly; the scale often moved more later. Treat the first month as the start of titration, not a referendum on whether the medication is working. Individual results vary.
For a deeper look at how GLP-1 weight loss tends to unfold over time, see our GLP-1 results timeline.
### Wegovy results by week
People often search for a week-by-week breakdown, hoping for a precise schedule. The STEP trials did not publish a tidy weekly weight figure for every single week, and even if they had, weekly numbers bounce around because of water, food timing, and normal day-to-day variation. What the trials do support is a phased view:
If you track weekly, expect zigzags. The trend over months is the signal; a single heavy or light week is noise. Individual results vary.
Factors That Change Individual Results
The STEP averages came from controlled trials with structured support. Real outcomes vary because real life has more variables. The biggest ones:
This is why the phrase repeats throughout responsible GLP-1 education: individual results vary. The trial numbers describe a group average, not a personal guarantee.
Plateaus Are Expected
A plateau is one of the most common worries, and it is also one of the most predictable. As body weight falls, the body requires fewer calories to function, so the same intake and the same dose produce a slower rate of loss. In the STEP trials the average weight curve flattened in the back half of the program as participants approached a new set point.
A plateau does not mean the medication has failed. If you hit one and have concerns, the right move is a conversation with your prescriber about dose, adherence, nutrition, activity, and realistic targets, not a self-directed change. Individual results vary.
What About Before and After
Searches for "Wegovy before and after" are common, and it is worth being careful here. Dramatic individual photos circulate widely online, but a single person's outcome is not a reliable predictor of yours, and many images online are unverified or unrelated. The trustworthy version of "before and after" is the published trial data: an average of 14.9% body weight reduction at week 68 in STEP-1, with a wide range around that average.
We do not publish patient before-and-after stories or photos, because individual anecdotes can set unrealistic expectations. The trial averages are the honest reference point. Individual results vary.
How Wegovy Compares to Tirzepatide
Patients often weigh Wegovy against tirzepatide (the molecule in Zepbound and Mounjaro). In its pivotal SURMOUNT-1 trial (NEJM 2022), tirzepatide produced larger average reductions: up to 20.9% body weight reduction at the highest dose at 72 weeks, versus Wegovy's 14.9% at week 68 in STEP-1.
Those are two separate trials with different participants and timelines, so this is not a head-to-head comparison. The larger SURMOUNT-1 average is notable, but the right medication depends on your medical history, tolerability, cost, and access, a decision for you and your prescriber. For a closer look at semaglutide brands specifically, see our breakdown of Ozempic vs Wegovy. Individual results vary.
Compounded Semaglutide
Cost and supply lead many patients to ask about compounded semaglutide. Compounded semaglutide uses the same active ingredient as Wegovy, but it is prepared by a state-licensed compounding pharmacy under a physician prescription for an individual patient, rather than being manufactured as a brand-name finished product.
Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered. One more honesty point: the weight loss percentages throughout this article come from trials of brand-name semaglutide (STEP-1, STEP-3, STEP-4, STEP-5). Those specific trials studied the branded product, not compounded preparations, so the published averages should be read with that in mind. Individual results vary.
If you want to understand this option in more detail, read our guide to compounded semaglutide, and you can review current options on our pricing page.
Supporting Your Results
The medication does meaningful work on appetite, but the STEP trials were not medication-only studies. Every arm paired semaglutide with a structured program. A few habits consistently show up in obesity medicine as supportive of better and more durable outcomes:
None of these turn an average into a promise. They are the conditions under which the published averages were achieved. Individual results vary.
Who Wegovy Is For
Wegovy is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It is also approved to reduce cardiovascular risk in certain adults with overweight or obesity and established cardiovascular disease.
It is not appropriate for everyone. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and those with certain other conditions, are generally not candidates. The only way to know whether it fits your situation is an evaluation with a licensed prescriber who reviews your full history. Individual results vary.
Putting the Numbers in Context
Here is the full set of named trial averages in one place, so the figures stay anchored to their source:
| Trial | Population | Endpoint | Semaglutide 2.4 mg average | Source |
|---|---|---|---|---|
| STEP-1 | Obesity/overweight, no diabetes | Week 68 | 14.9% | NEJM 2021 |
| STEP-3 | With intensive behavioral therapy | Week 68 | ~16.0% | JAMA 2021 |
| STEP-4 | Continued vs stopped at week 20 | Week 68 | ~17.4% (continued) vs ~5% (stopped) | JAMA 2021 |
| STEP-5 | Two-year treatment | Week 104 | ~15.2% | Nature Medicine 2022 |
| SURMOUNT-1 (tirzepatide) | Obesity/overweight, no diabetes | Week 72 | up to 20.9% | NEJM 2022 |
Every number above is a group average from a named study, reported with lifestyle support as part of the protocol. None of them is a forecast for any one person. Individual results vary.
The Bottom Line
Wegovy's published trial results are genuinely strong: an average of 14.9% body weight reduction at week 68 in STEP-1, sustained near 15.2% at two years in STEP-5, with meaningful regain when the medication stops (STEP-4). The realistic timeline is gradual, shaped by a slow titration, with plateaus along the way that are normal rather than a sign of failure.
What none of this provides is a promise. The trials describe averages across thousands of people who also followed structured diet and activity support, and the range around those averages was wide. Whether Wegovy, another GLP-1, or a compounded option is right for you is a medical decision made with a licensed prescriber who knows your history. Individual results vary.
This article is for educational purposes and is not medical advice. Talk with a licensed healthcare provider about whether a GLP-1 medication is appropriate for you.
Frequently Asked Questions
How much weight do people lose on Wegovy on average?
In the STEP-1 trial (NEJM 2021), adults with obesity or overweight who took Wegovy (semaglutide 2.4 mg) lost an average of 14.9% of their body weight at week 68, compared with 2.4% in the placebo group. About one in three participants lost 20% or more of their body weight. These are published trial averages, not a guarantee. Individual results vary based on dose adherence, diet, activity, starting weight, and personal biology.
How fast does Wegovy work?
Wegovy is titrated slowly over about 16 to 20 weeks, so weight loss tends to build gradually rather than all at once. In the STEP trials, participants were still on low starter doses during the first month, so early weight changes were modest. Most of the average reduction accumulated across months four through twelve as the dose reached the 2.4 mg target. Individual results vary, and your prescriber sets the titration pace based on how you tolerate the medication.
What weight loss can I expect in the first month on Wegovy?
The first month on Wegovy is the starter phase, typically 0.25 mg per week, which is a tolerability dose rather than a full therapeutic dose. Because of that, first-month weight changes in the STEP trials were generally small and varied widely from person to person. Some people notice reduced appetite quickly while the scale moves little at first. The larger average reductions reported in STEP-1 came later in the program. Individual results vary.
Does weight come back after you stop Wegovy?
Published data suggest weight regain is common after stopping. In the STEP-4 trial (JAMA 2021), participants who stopped semaglutide at week 20 regained much of the lost weight over the following year, while those who continued kept losing. The STEP-1 extension showed a similar pattern after the medication and lifestyle support ended. This is why clinicians treat obesity as a chronic condition that often needs ongoing management rather than a short course. Individual results vary.
Why has my Wegovy weight loss plateaued?
Plateaus are an expected part of any weight management program. As body weight drops, the body needs fewer calories, so the rate of loss naturally slows even when the medication and habits stay the same. In the STEP trials the average weight loss curve flattened in the second half of the program as participants approached a new set point. A plateau does not mean the medication stopped working. If you have concerns, your prescriber can review dose, adherence, diet, and activity. Individual results vary.
Is Wegovy or tirzepatide more effective for weight loss?
Across separate trials, tirzepatide produced larger average reductions. In SURMOUNT-1 (NEJM 2022), the highest tirzepatide dose averaged up to 20.9% body weight reduction at 72 weeks, while Wegovy averaged 14.9% at week 68 in STEP-1. These were different studies with different populations, so the numbers are not a head-to-head result. The right choice depends on your medical history, tolerability, cost, and access. Individual results vary.
Is compounded semaglutide the same as Wegovy?
Compounded semaglutide uses the same active ingredient as Wegovy but is not the same final product. Wegovy is an FDA-approved finished drug made by Novo Nordisk. Compounded semaglutide is prepared by a state-licensed compounding pharmacy under a physician prescription for an individual patient. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered. The published weight loss numbers in this article come from trials of brand-name semaglutide, not compounded preparations.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner, MD Integrations (MDI). Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through the MD Integrations Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)